Want to see CH:ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
CHF0.04
<CHF0.01(5.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF0.03 - CHF0.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)206.07K
Market Cap
CHF4.72M
Enterprise ValueCHF3.74
Total Cash (Recent Filing)CHF937.50K
Total Debt (Recent Filing)CHF102.27K
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding218,654,500
10 Day Avg. Volume188,431
30 Day Avg. Volume206,072
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.30
Price to Sales (P/S)35.91
P/FCF Ratio-2.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Scientific / Preclinical MomentumRobust cross-species efficacy and favorable safety margins materially de-risk the GABAB PAM program over the next months. IND‑enabling studies are ready subject to financing, making this a durable technical asset that increases the likelihood of partnership or clinical advancement once funding is secured.
Partnership Upside (Indivior)A large, structured collaboration provides non-dilutive upside and potential funding tied to development milestones. This deal architecture reduces reliance on sole internal funding, creates multi-year optionality for revenue realization, and materially improves strategic flexibility if partner progresses programs.
Low Leverage Balance SheetVery low indebtedness lowers solvency risk and preserves capacity to negotiate financings or partnerships under less strained covenants. While cash is limited, minimal debt is a durable structural strength that helps sustain operations and optionality during a multi-month development cycle.
Bears Say
Insufficient Cash RunwayCash under CHF 1m and runway only into Q4 2026 means the company cannot self-fund unpartnered IND starts or early clinical activity. This creates near-term financing urgency that will likely force dilutive raises or reliance on partner deals, materially raising execution risk over the next 2–6 months.
Persistent Cash BurnSustained negative operating and free cash flow, despite moderation versus prior years, means the business cannot self-sustain development pacing. Continued cash burn necessitates external financing, increasing dilution risk and constraining the company's ability to independently advance multiple programs simultaneously.
Contracting Revenue & Deep LossesSignificantly shrinking revenue and very large losses relative to the revenue base reduce internal funding capacity and weaken returns on equity. This structural profitability deficit hampers reinvestment, increases dependence on milestone or financing events, and raises the bar for partner interest.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was CHF0.03 and its highest was CHF0.09 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is CHF4.72M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 34 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Jun 25, 2026. The company reported -CHF0.01 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Undervalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 218,654,500 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -CHF0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.762%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in CH:ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.